cytarabine has been researched along with Lymphoma, Mantle-Cell in 147 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 35 (23.81) | 29.6817 |
| 2010's | 80 (54.42) | 24.3611 |
| 2020's | 32 (21.77) | 2.80 |
| Authors | Studies |
|---|---|
| Allmer, C; Ansell, SM; Castellino, A; Cerhan, JR; Cohen, JB; Farooq, U; Feldman, AL; Habermann, TM; Inwards, DJ; Larson, MC; Link, BK; Martin, P; Maurer, MJ; Nowakowski, GS; Paludo, J; Slager, SL; Syrbu, SI; Wang, Y; Witzig, TE | 1 |
| Carlsten, M; Christensson, B; de Matos Rodrigues, J; Ek, S; Herold, N; Jerkeman, M; Kolstad, A; Ljung, E; Merrien, M; Morsy, MHA; Rassidakis, GZ; Sander, B; Wahlin, BE; Wasik, AM | 1 |
| Badillo, M; Fayad, L; Feng, L; Flowers, CR; Fowler, N; Hagemeister, FB; Hill, HA; Iyer, SP; Jain, P; Jorgensen, J; Kanagal-Shamanna, R; Lee, HJ; Li, S; Lin, P; Medeiros, LJ; Nair, R; Nastoupil, L; Navsaria, L; Nogueras Gonzalez, GM; Ok, CY; Patel, KP; Samaniego, F; Santos, D; Steiner, R; Tang, G; Thirumurthi, S; Vega, F; Wagner-Bartak, N; Wang, L; Wang, ML; Wang, SA; Westin, JR; Xu, G; Xuelin, H; Yao, Y; Yin, CC; Zhao, S | 1 |
| Yamamoto, K; Yanada, M | 1 |
| Bouabdallah, K; Casasnovas, RO; Costes-Tertrais, D; Damaj, G; Dartigeas, C; Delette, C; Fogarty, P; Fornecker, LM; Garciaz, S; Gastinne, T; Gressin, R; Houot, R; Hueso, T; Le Gouill, S; Malak, S; Oberic, L; Ribrag, V; Tchernonog, E; Thieblemont, C | 1 |
| Bosly, A; Dreyling, M; Freeman, CL; Gerrie, AS; Hermine, O; Hoster, E; Klapper, W; Ramsower, CA; Rimsza, LM; Savage, KJ; Scott, DW; Sehn, LH; Szymczyk, M; Unterhalt, M; Villa, D | 1 |
| Cohen, JB; Daly, K; Grover, NS; Hill, B; Kahl, B; Kumar, A; Maddocks, K; Martin, P; Parisi, L; Qi, K; Salles, G; Switchenko, JM; Villa, D; Wang, M; Zhu, A | 1 |
| Alanne, E; Harmanen, M; Hujo, M; Jantunen, E; Jukkola, A; Kari, E; Khan, M; Klaavuniemi, T; Kuittinen, O; Kuitunen, H; Prusila, R; Rajamäki, A; Rönkä, A; Sancho, JM; Sorigue, M; Sund, R; Sunela, K | 1 |
| Bao, HZ; Cai, QQ; Dong, YJ; He, J; Huang, WR; Jing, HM; Li, LH; Li, XL; Li, ZL; Liu, AC; Liu, H; Liu, SZ; Sun, XH; Wang, JW; Wang, SY; Wang, YL; Xiao, XB; Yang, P; Yang, W; Zhang, W | 1 |
| Arcari, A; Botto, B; Bruna, R; Celli, M; Cencini, E; Chini, C; Di Rocco, A; Evangelista, A; Ferrante, M; Ferrero, S; Ghiggi, C; Merli, F; Moia, R; Patti, C; Pileri, SA; Puccini, B; Quaglia, FM; Re, A; Sciarra, R; Spina, M; Stelitano, C; Tani, M; Tisi, MC; Visco, C; Volpetti, S; Zambello, R; Zanni, M; Zilioli, VR | 1 |
| Bartlett, NL; Cashen, A; Edwin, N; Fehniger, TA; Ghobadi, A; Guy, DG; Kahl, BS; Patel, DA; Shah, NM; Trinkaus, K; Wan, F; Watkins, M | 1 |
| Ishiwata, K; Kageyama, K; Kaji, D; Mori, YA; Nishida, A; Shimizu, Y; Takagi, S; Taniguchi, S; Taya, Y; Uchida, N; Wake, A; Watanabe, O; Yamaguchi, K; Yamamoto, G; Yamamoto, H | 1 |
| Cai, Q; Che, Y; Deng, J; Fang, Y; Fei, Y; Feng, J; He, Y; Huang, H; Liang, R; Liang, Y; Liu, P; Lv, H; Lv, Y; Pan, T; Qiu, L; Sun, X; Wang, M; Wang, Y; Xiao, L; Ye, H; Yi, S; Zeng, D; Zhang, H; Zhou, H; Zou, D | 1 |
| Byun, JM; Choi, YS; Do, YR; Hong, J; Kim, DS; Kim, I; Kim, KH; Kim, WS; Koh, Y; Lee, GW; Lee, JY; Park, Y; Shin, J; Yoon, SS | 1 |
| Campbell, P; Casan, J; Chai, KL; Gilbertson, M; Grigoriadis, G; Hawkes, E; Htet, SM; Htun, KT; McQuilten, Z; Opat, S; Patil, S; Quach, H; Ratnasingam, S; Shortt, J | 1 |
| Abraham, J; Borel, C; Bouabdallah, K; Bouabdallah, R; Casasnovas, RO; Chantepie, S; Damaj, G; Delapierre, B; Delette, C; Durot, E; Fornecker, LM; Garciaz, S; Gastinne, T; Gressin, R; Gyan, E; Houot, R; Hueso, T; Ibrahim, A; Le Gouill, S; Lemal, R; Malak, S; Morello, R; Peyrade, F; Tchernonog, E; Tessoulin, B; Tournilhac, O | 1 |
| Crosbie, N; Eyre, TA; Frewin, R; Lambert, J; McCulloch, R; McMillan, A; Phillips, N; Quaglia, FM; Rule, S; Tucker, DL; Visco, C | 1 |
| Aldrees, S; Jeeva-Patel, T; Margolin, E | 1 |
| Armand, P; Bartlett, NL; Brown, JR; Bsat, J; Cashen, A; Chase, M; Crombie, J; Davids, MS; Edwin, N; Fisher, D; Freedman, A; Ghobadi, A; Jacene, H; Jacobsen, E; Jacobson, C; Joyce, R; Kahl, B; Kim, A; LaCasce, A; Mehta-Shah, N; Merryman, RW; Ng, S; Odejide, O; Redd, R | 1 |
| Böhmer, LH; Chitu, DA; de Jong, D; de Jongh, E; de Weerdt, O; Doorduijn, JK; Hoogendoorn, M; Kersten, MJ; Kibbelaar, RE; Kluin-Nelemans, HC; Leys, RBL; Lugtenburg, PJ; MacKenzie, MA; Minnema, MC; Snijders, TJF; van Gelder, M; van Marwijk Kooij, R; Van't Veer, MB; Zijlstra, JM | 1 |
| Angrilli, F; Federico, M; Galimberti, S; Luminari, S; Manni, M; Marcheselli, L; Massaro, F; Merli, F; Petrini, M; Stelitano, C; Stepanishyna, Y; Tecchio, C; Visco, C | 1 |
| de Castro, DG; Dietrich, S; Dreger, P; Dreyling, M; Grabe, N; Hermine, O; Hoster, E; Hüttl, K; Klapper, W; Kluin-Nelemans, HC; Müller-Tidow, C; Ott, G; Pott, C; Roider, T; Rosenwald, A; Stewart, JP; Wang, X | 1 |
| Bonaldi, L; Branca, A; Gurrieri, C; Manni, S; Martines, A; Piazza, F; Pizzi, M; Riva, M; Scapinello, G; Semenzato, G; Trentin, L; Visentin, A | 1 |
| Guy, D; Kahl, BS | 1 |
| Böhmová, E; Etrych, T; Helman, K; Karolová, J; Klener, P; Pankrác, J; Pechar, M; Pokorná, E; Pola, R; Šefc, L; Trněný, M; Vočková, P | 1 |
| Anusim, N; Gupta, A; Howard, G; Jaiyesimi, I | 1 |
| Arasaretnam, A; Bishton, M; Bolam, S; Creasey, T; Crosbie, N; Dawi, S; Dutton, D; Eyre, TA; Follows, G; Goradia, H; Harrison, S; Johnston, R; Kirkwood, AA; Lambert, J; Lewis, D; McCulloch, R; McKay, P; McMillan, A; Miles, O; Osborne, W; Patmore, R; Phillips, N; Robinson, A; Rule, S; Wilson, MR | 1 |
| Bouadballah, K; Casasnovas, O; Chiron, D; Damaj, G; Feugier, P; Gressin, R; Gyan, E; Hermine, O; Joubert, C; Lamy, T; Le Gouill, S; Lemonnier, F; Maisonneuve, H; Moreau, A; Oberic, L; Ribrag, V; Tessoulin, B; Thieblemont, C; Tilly, H; Van Den Neste, E; Zerazhi, H | 1 |
| Alderuccio, JP; Alencar, AJ; Iyer, SG; Lossos, IS; Reis, IM; Rosenblatt, JD; Saul, EE | 1 |
| Bachanova, V; Badar, T; Barta, SK; Blum, KA; Bond, DA; Burkart, M; Calzada, O; Churnetski, MC; Cohen, JB; Danilov, AV; Epperla, N; Fenske, TS; Flowers, CR; Gerson, JN; Ghosh, N; Gordon, MJ; Goyal, S; Grover, NS; Guo, J; Hamadani, M; Hill, BT; Kahl, BS; Karmali, R; Kolla, B; Malecek, M; Martin, P; Mathews, S; Park, SI; Sawalha, Y; Shanmugasundaram, K; Switchenko, J | 1 |
| Guerra, R; Saavedra, AP; Yi, LG | 1 |
| Chan, JY; Chang, EWY; Farid, M; Khoo, LP; Lim, ST; Poon, E; Somasundaram, N; Tang, TPL; Tao, M; Yang, VS; Yang, X | 1 |
| Albo, C; Arranz, R; Cannata-Ortiz, J; Conde, E; Debén, G; García-Noblejas, A; García-Ruiz, JC; González Barca, E; González de Villambrosia, S; Gutiérrez, N; Jiménez-Ubieto, A; López, A; López-Guillermo, A; Martín García-Sancho, A; Mercadal, S; Nicolás, C; Novelli, S; Ramírez, MJ; Ríos Rull, P; Rojas, R; Sancho, JM; Vidal, MJ | 1 |
| Cohen, JB; Kahl, BS; Zain, JM | 1 |
| Béné, MC; Bouabdallah, K; Callanan, M; Canioni, D; Cartron, G; Casasnovas, O; Damaj, G; Dartigeas, C; Feugier, P; Fornecker, LM; Gastinne, T; Gressin, R; Haioun, C; Hermine, O; Houot, R; Jardin, F; Lamy, T; Le Dû, K; Le Gouill, S; Maisonneuve, H; Moreau, A; Morschhauser, F; Oberic, L; Ribrag, V; Salles, G; Thieblemont, C; Tilly, H; Tournilhac, O; Van Den Neste, E; Zerazhi, H | 1 |
| Cassaday, RD; Cowan, A; Ermoian, R; Gopal, AK; Graf, SA; Holmberg, LA; Press, OW; Shadman, M; Smith, SD; Stevenson, PA; Till, BG; Tseng, YD | 1 |
| Belada, D; Berkova, A; Blahovcova, P; Campr, V; Forsterova, K; Fronkova, E; Jaksa, R; Janikova, A; Kalinova, M; Klener, P; Kodet, R; Kubinyi, J; Markova, J; Mejstrikova, E; Michalova, K; Mocikova, H; Obr, A; Prochazka, V; Pytlik, R; Salek, D; Simkovic, M; Trka, J; Trneny, M; Vaskova, M | 1 |
| Balabanov, S; Gerber, B; Goede, JS; Manz, MG; Samaras, P; Soldini, D; Widmer, F | 1 |
| Lavolé, J; Le Goff, M; Mallet, V; Oudjit, A; Sogni, P | 1 |
| Martin, P | 2 |
| Bongers, KS; Ettleson, M; Marini, BL; Perissinotti, AJ; Phillips, T; Vitale, K | 1 |
| McCulloch, R; Rule, S | 1 |
| Ek, F; Ek, S; Emruli, VK; Eskelund, CW; Freiburghaus, C; Grønbæk, K; Jerkeman, M; Johansson, A; Olsson, R | 1 |
| Fanale, M; Fayad, LE; Feng, L; Ford, P; Fowler, N; Goy, A; Hagemeister, F; Hartig, K; Kantarjian, HM; Kwak, LW; McLaughlin, P; Medeiros, LJ; Naig, A; Neelapu, S; Oki, Y; Orlowski, R; Pro, B; Rodriguez, MA; Romaguera, JE; Samaniego, F; Smith, J; Valentinetti, M; Wang, M; Younes, A | 1 |
| Ando, K; Fukuhara, N; Gomyo, H; Hanamura, I; Hotta, T; Kobayashi, H; Kobayashi, N; Kumagai, K; Kurosawa, M; Maruyama, D; Matsuno, Y; Miyazaki, K; Morishima, Y; Nagai, H; Nakamura, S; Nosaka, K; Ogura, M; Ohmachi, K; Ohnishi, K; Ohyashiki, K; Sawada, K; Shimoyama, T; Takayama, N; Taniwaki, M; Tobinai, K; Tsukamoto, N; Tsukasaki, K; Uike, N; Usuki, K; Utsumi, T; Wakabayashi, M; Yakushijin, Y; Yamamoto, K | 1 |
| Busam, KJ; Dickson, MA; Geller, S; Myskowski, PL | 1 |
| Edwin, NC; Kahl, B | 1 |
| An, R; Hu, K; Jing, HM; Ke, XY; Liu, YY; Pang, M; Wan, W; Yang, P; Zhao, W; Zhen, JF | 1 |
| Alvarez De Celis, I; Arcari, A; Chiappella, A; Cox, MC; Di Rocco, A; Dreyling, M; Evangelista, A; Fabbri, A; Ferrero, S; Finolezzi, E; Gentile, M; Gini, G; Hermine, O; Hohaus, S; Hoster, E; Loseto, G; Marino, D; Martelli, M; Merli, M; Molinari, AL; Morello, L; Nassi, L; Pelosini, M; Perrone, T; Piazza, F; Puccini, B; Re, A; Ruggeri, M; Sciarra, R; Tecchio, C; Tisi, MC; Visco, C; Vitolo, U; Zilioli, VR; Zoellner, AK | 1 |
| Cowan, A; Gandhy, S; Gopal, AK; Hill, BT; Kanan, S; Low, L; Lynch, RC; Reddy, P; Shadman, M; Smith, SD; Till, BG | 1 |
| Campbell, J; Ernst, D; Hurtado, S; Kutz, C; Soto, K | 1 |
| Altuntaş, F; Bakırtaş, M; Başçı, S; Batgi, H; Bekdemir, F; Çakar, MK; Dal, MS; İskender, D; Kaya, AH; Merdin, A; Tekgündüz, E; Uğur, B; Ulu, BU; Yiğenoğlu, TN; Yıldız, J | 1 |
| Bishton, M; Campbell, R; Cheah, CY; Cochrane, T; De Mel Widanalage, S; Gilbertson, M; Hapgood, G; Hawkes, E; Hill, K; Johnston, A; Lee, HP; Manos, K; Nelson, N; Ng, M; Ng, ZY; Opat, S; Poon, M; Purtill, D; Ratnasingam, S; Ritchie, D; Schwarer, A; Seymour, J; Shorten, S; Sunny, T; Tam, C; Xin, L | 1 |
| Bernstein, SH; Burack, R; Cebula, E; Epner, E; Fisher, RI; Leblanc, M; Miller, TP; Rimsza, L; Unger, JM | 1 |
| Aláez, C; Arranz, E; Arranz, R; Caballero, D; Canales, MA; Cannata-Ortiz, J; Conde, E; García-Marco, JA; García-Noblejas, A; Grande, C; Martín, A; Martínez-Sánchez, P; Pérez-Calvo, J; Salar, A; Sánchez, JJ; Sánchez-González, B; Terol, MJ | 1 |
| Alousi, AM; Anderlini, P; Betul, O; Bueso-Ramos, C; Chakhachiro, ZI; Champlin, R; Ciurea, SO; Khouri, IF; Korbling, M; Medeiros, LJ; Okoroji, GJ; Popat, U; Saliba, RM; Samuels, BI | 1 |
| Bertoni, F; Cavalli, F; Conconi, A; de Campos, CP; Franceschetti, S; Gaidano, G; Ghielmini, M; Margiotta Casaluci, G; Stathis, A; Stussi, G; von Hohenstaufen, KA; Zucca, E | 1 |
| Drach, J; Kiesewetter, B; Lamm, W; Mayerhöfer, ME; Müllauer, L; Raderer, M; Zielinksi, CC | 1 |
| Geisler, CH; Jerkeman, M; Kolstad, A; Laurell, A; Räty, R | 1 |
| Bouabdallah, K; Bouabdallah, R; Cacheux, V; Cartron, G; Casasnovas, O; Compain, L; Damaj, G; Delarue, R; Gressin, R; Gyan, E; Hermine, O; Le Gouill, S; Leux, C; Michallet, AS; Milpied, N; Mohty, M; Moles, MP; Morschhauser, F; Rose, C; Roussel, M; Sirvent, A; Thieblemont, C; Touzeau, C | 2 |
| Allen, MS; Armitage, JO; Bierman, PJ; Bociek, RG; Loberiza, FR; Vose, JM; William, BM | 1 |
| Akutsu, M; Furukawa, Y; Hiraoka, N; Kano, Y; Kikuchi, J; Koyama, D; Mori, S; Nakamura, Y; Ueda, T; Uesawa, M; Wada, T; Yamauchi, T | 1 |
| Bentzen, H; Bogsrud, TV; Brown, Pde N; Delabie, J; Ehinger, M; Elonen, E; Fagerli, UM; Frederiksen, H; Geisler, CH; Grønbæk, K; Hansen, PB; Jerkeman, M; Karjalainen-Lindsberg, ML; Kimby, E; Kolstad, A; Kostova-Aherdan, K; Laurell, A; Lauritzsen, GF; Lehmann, AK; Loft, A; Nilsson-Ehle, H; Pedersen, LB; Ralfkiaer, E; Räty, R; Schildt, J; Sundstrom, C | 1 |
| Di Raimondo, F; Doorduijn, J; Dreyling, MH; Forstpointner, R; Geisler, CH; Hallek, M; Hermine, O; Hiddemann, W; Hoster, E; Klapper, W; Kluin-Nelemans, HC; Pott, C; Ribrag, V; Stilgenbauer, S; Szymczyk, M; Thieblemont, C; Trneny, M; Unterhalt, M; van Hoof, A; Walewski, J | 1 |
| Ogura, M | 1 |
| Dreyling, M; Ferrero, S; Hermine, O | 1 |
| Hernandez, F; Jaksa, R; Klanova, M; Klener, P; Kulvait, V; Lateckova, L; Lorkova, L; Maswabi, B; Mavis, C; Molinsky, J; Petrak, J; Pospisilova, J; Trneny, M; Vejmelkova, D; Vit, O; Vockova, P; Vokurka, M | 1 |
| Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 1 |
| Caballero, D; Corradini, P; Dreger, P; Dreyling, M; Geisler, C; Ghielmini, M; Hermine, O; Kimby, E; Le Gouill, S; Robinson, S; Rule, S; Vitolo, U | 1 |
| Campo, E; Rule, S | 1 |
| Banz, Y; Berger, MD; Branger, G; Klaeser, B; Mueller, BU; Novak, U; Pabst, T; Taleghani, BM | 1 |
| Berger, F; Briere, J; Casasnovas, O; Delfau-Larue, MH; Dreyling, M; Feugier, P; Haioun, C; Hermine, O; Hoster, E; Jardin, F; Klapper, W; Macintyre, E; Pott, C; Ribrag, V; Salles, G; Thieblemont, C; Unterhalt, M | 1 |
| Caimi, PF; Campagnaro, EL; Cooper, BW; Creger, RJ; de Lima, M; Fox, R; Fu, P; Gerson, SL; Lazarus, HM; Reese-Koc, J; Silva Rondon, CH; William, BM | 1 |
| Bloehdorn, J; Doorduijn, J; Dreyling, M; Geisler, CH; Hallek, M; Hermine, O; Hoster, E; Jerkeman, M; Klapper, W; Kluin-Nelemans, JC; Kolstad, A; Laurell, A; Pott, C; Räty, R; Ribrag, V; Salles, G; Szymczyk, M; Unterhalt, M; van der Holt, B; Van't Veer, M; Walewski, J | 1 |
| Cabanillas, F; Cheah, CY; Chihara, D; Fayad, LE; Goy, A; Hagemeister, FB; Kantarjian, H; Kwak, LW; McLaughlin, P; Pro, B; Rodriguez, MA; Romaguera, JE; Samaniego, F; Wang, ML; Westin, JR; Younes, A | 1 |
| Armand, P; Brown, JR; Bsat, J; Davids, MS; Faham, M; Fisher, DC; Freedman, AS; Giardino, A; Jacobsen, ED; Jacobson, C; Joyce, R; LaCasce, AS; Mayuram, S; Redd, R; Weng, L; Wilkins, J | 1 |
| Cheah, CY; Seymour, JF; Wang, ML | 1 |
| Boulahdour, H; Daguindau, E; Deconinck, E; Helias, P; Philippe, L; Puyraveau, M | 1 |
| Alonso, JJ; Cánovas, A; Riñón, MM | 1 |
| García, O; Moreno, M; Ribera, JM; Sancho, JM; Sorigue, M; Vila, J | 1 |
| Birkmann, J; Bosly, A; Bouabdallah, K; Bouabdallah, R; Brousse, N; Casasnovas, RO; Delarue, R; Delfau-Larue, MH; Dreyling, M; Dührsen, U; Feugier, P; Finke, J; Fischer, T; Forstpointner, R; Haioun, C; Hallek, M; Hänel, M; Hermine, O; Hiddemann, W; Hoster, E; Kanz, L; Klapper, W; Kneba, M; Macintyre, E; Maschmeyer, G; Metzner, B; Peter, N; Pott, C; Ribrag, V; Salles, G; Schmidt, C; Sebban, C; Stilgenbauer, S; Szymczyk, M; Thieblemont, C; Unterhalt, M; Walewski, J | 1 |
| Romero, D | 1 |
| Alam, M; Klanova, M; Klener, P; Lateckova, L; Molinsky, J; Soukup, T; Trneny, M; Vockova, P; Zivny, J | 1 |
| Rule, S | 1 |
| Lipsky, A; Martin, P | 1 |
| Barr, PM; Bernstein, SH; Blum, KA; Cashen, AF; Chen, RW; Cheson, BD; Constine, L; Faham, M; Fenske, TS; Fisher, RI; Forman, SJ; Friedberg, JW; Kahl, BS; Kahwash, S; Leblanc, M; Leonard, JP; Li, H; Phillips, T; Rimsza, LM; Shea, TC; Smith, SM; Wilkins, J | 1 |
| André, M; Beel, K; Bonnet, C; Boulet, D; Caron, C; De Samblanx, H; Debussche, S; Delrieu, V; Jacquy, C; Janssens, A; Lemmens, J; Madoe, V; Maerevoet, M; Maertens, V; Meers, S; Pranger, D; Schauvlieghe, L; Schroyens, W; Van Den Broeck, I; Van Den Neste, E; Van Eygen, K; Van Hende, V; Van Hoof, A; Vanstraelen, G; Vergote, V; Verhoef, G | 1 |
| Ahn, HK; Chang, MH; Kim, SJ; Kim, WS; Lee, SJ; Yi, JH | 1 |
| Colgan, JP; Dalton, RJ; Geyer, SM; Inwards, DJ; Kurtin, PJ; LaPlant, BR; Micallef, IN; Michalak, JC; Moore, DF; Reeder, CB; Salim, M; Witzig, TE | 1 |
| Cabanillas, F; Fayad, L; Hagemeister, F; Kantarjian, H; Kwak, LW; McLaughlin, P; Rodriguez, MA; Romaguera, J; Wang, M; Zhou, Y | 1 |
| de Jong, D; Hagenbeek, A; Kluin-Nelemans, HC; MacKenzie, M; van 't Veer, MB; van Oers, MH; van Putten, WL; Zijlstra, J | 1 |
| Dreyling, M; Hiddemann, W | 1 |
| Garcia, M; Inamdar, KV; Medeiros, LJ; Rassidakis, GZ; Romaguera, JE | 1 |
| Bentz, M; Dreyling, M; Hiddemann, W; Jentsch-Ullrich, K; Mueck, R; Rohrberg, R; von Schilling, C; Weidmann, E; Weigert, O | 1 |
| Geisler, C; Kolstad, A; Laurell, A; Räty, R | 1 |
| Khouri, IF; Tam, CS | 1 |
| Drakos, E; Garcia, M; Inamdar, KV; Knoblock, RJ; Leventaki, V; Medeiros, LJ; Rassidakis, GZ; Romaguera, JE | 1 |
| Bartlett, NL; Blum, KA; Byrd, JC; Canellos, GP; Cheson, BD; Damon, LE; Hurd, DD; Johnson, JL; Kelly, M; Lacasce, AS; Linker, CA; Niedzwiecki, D; Stock, W | 1 |
| Byrne, GE; Coleman, F; Escalón, MP; Hosein, PJ; Lossos, IS; Morgensztern, D; Rosenblatt, JD; Walker, GR | 1 |
| Hashimoto, C; Ishigatsubo, Y; Motomura, S; Takasaki, H; Takemura, S | 1 |
| Casassus, P; Caulet-Maugendre, S; Celigny, PS; Colombat, P; Colonna, M; Cornillon, J; Corront, B; Damaj, G; Deconinck, E; El Yamani, A; Gressin, R; Gyan, E; Lamy, T; Le Gouill, S; Lepeu, G; Maisonneuve, H; Moles, MP; Rossi, JF; Tournilhac, O; Vilque, JP | 1 |
| Ali-Osman, F; Beaven, A; Chao, NJ; Chute, J; Crout, CA; Davis, P; Decastro, C; Diehl, L; Edwards, J; Gasparetto, C; Gockerman, JP; Horwitz, M; Koh, LP; Long, GD; Moore, JO; Morris, A; Niedzwiecki, D; Prosnitz, L; Rizzieri, DA | 1 |
| Cabanillas, F; Fayad, LE; Feng, L; Goy, A; Hagemeister, FB; Hartig, K; Kantarjian, H; Kwak, L; McLaughlin, P; Pro, B; Rodriguez, MA; Romaguera, JE; Samaniego, F; Wang, M; Weaver, P; Younes, A | 1 |
| Cain, M; Cull, GM; Hackett, LP; Ilett, KF; Radeski, D | 1 |
| Schneider, AE; Talmon, GA | 1 |
| Geisler, CH | 2 |
| Fayad, LE; Feldman, T; Ford, P; Goldberg, S; Goy, A; Hartig, K; Kwak, LW; McLaughlin, P; Pecora, A; Pro, B; Rodriguez, A; Romaguera, JE; Smith, J; Wang, M; Weaver, P | 1 |
| Barbarat, A; Houlgatte, R; Raharijaona, M; Rolland, D; Thieblemont, C | 1 |
| Andresen, S; Bolwell, BJ; Copelan, E; Dean, R; Hill, BT; Kalaycio, M; Pohlman, B; Rybicki, L; Smith, S; Sobecks, R; Sweetenham, J; Tench, S | 1 |
| Bensinger, WI; Budde, LE; Chauncey, TR; Gopal, AK; Green, DJ; Guthrie, KA; Holmberg, LA; Maloney, DG; Pagel, JM; Petersdorf, SH; Press, OW; Shustov, AR; Till, BG | 1 |
| Albiero, E; Bernardi, M; Castegnaro, S; Chieregato, K; Madeo, D; Rodeghiero, F; Visco, C; Zanon, C | 1 |
| Ambrosetti, A; Angrilli, F; Barbolini, E; Capodanno, I; Caracciolo, F; Carella, AM; Di Renzo, N; Federico, M; Galimberti, S; Ilariucci, F; Luminari, S; Merli, F; Petrini, M; Stelitano, C; Visco, C | 1 |
| Elonen, E; Honkanen, T; Jantunen, E; Jyrkkiö, S; Karjalainen-Lindsberg, ML; Kuittinen, O; Lehto, M; Mikkola, M; Poikonen, E; Räsänen, A; Räty, R; Rauhala, A; Rimpiläinen, J; Siitonen, S; Suominen, M; Vapaatalo, M | 1 |
| Vose, JM | 1 |
| Andersen, NS; Bentzen, H; Brown, P; Delabie, J; Ehinger, M; Elonen, E; Eriksson, M; Geisler, CH; Jerkeman, M; Karjalainen-Lindsberg, ML; Kimby, E; Kolstad, A; Kuittinen, O; Laurell, A; Lauritzsen, GF; Nilsson-Ehle, H; Nordström, M; Pedersen, LB; Ralfkiaer, E; Räty, R; Sundström, C | 1 |
| Brice, P; Brousse, N; Casasnovas, O; Delarue, R; Delmer, A; Haioun, C; Hermine, O; Lefrere, F; Ribrag, V; Salles, G; Tilly, H; Van Hoof, A | 1 |
| Camara-Clayette, V; Hermine, O; Ribrag, V | 1 |
| Bolam, S; Farrell, K; Forbes, A; McKay, P; Rule, S | 1 |
| D'Amore, ES; Finotto, S; Menin, A; Paolini, R; Pizzolo, G; Rodeghiero, F; Semenzato, G; Visco, C; Zaja, F; Zambello, R; Zanotti, R | 1 |
| Elonen, E; Franssila, K; Itälä, M; Jantunen, E; Kuittinen, O; Lehtinen, T; Oinonen, R; Wiklund, T | 1 |
| Hino, N; Ishibashi, K; Kanaji, N; Uno, H | 1 |
| Barbui, T; Benedetti, F; Capria, S; Carlo-Stella, C; Corradini, P; Cortelazzo, S; Di Nicola, M; Gianni, AM; Magni, M; Martelli, M; Parvis, G; Patti, C; Pilotti, S; Rambaldi, A; Tarella, C | 1 |
| Arai, M; Fujii, H; Kojima, Y; Koyama, F; Matsumoto, H; Mukogawa, T; Nakajima, Y; Takeuchi, T; Yagi, H | 1 |
| Bruning, R; Dühmke, E; Pachmann, S; Schaffer, M | 1 |
| Freedman, A; Jacobsen, E | 1 |
| Alessandrino, EP; Arcaini, L; Bernasconi, P; Bonfichi, M; Brusamolino, E; Calatroni, S; Iacona, I; Lazzarino, M; Montanari, F; Orlandi, E; Pascutto, C; Regazzi, M; Tenore, A; Troletti, D | 1 |
| Hashimoto, R; Iwakiri, R; Mori, M; Ohta, M; Tsutsumi, H | 1 |
| Delarue, R; Delmer, A; Hermine, O; Lefrère, F; Levy, V; Varet, B | 1 |
| Horiike, S; Kanbayashi, Y; Matsumoto, Y; Mukoyama, N; Nishida, K; Nomura, K; Shimizu, D; Taniwaki, M | 1 |
| Bernard, M; Bordessoule, D; de Guibert, S; Jaccard, A; Lamy, T; Turlure, P | 1 |
| Dörken, B; Dreyling, M; Forstpointner, R; Freund, M; Ganser, A; Hiddemann, W; Hoster, E; Huber, C; Ludwig, WD; Nickenig, C; Trümper, L; Unterhalt, M | 1 |
| Astolfi, M; Boccadoro, M; Bodoni, CL; De Marco, F; Drandi, D; Gianni, AM; Guidetti, A; Ladetto, M; Magni, M; Mantoan, B; Matteucci, P; Pagliano, G; Ricca, I; Tarella, C; Zanni, M | 1 |
| Dreyling, M; Hiddemann, W; Lang, N; Pastore, A; Rieken, M; Weigert, O | 1 |
| Falk, P; Forman, SJ; Fung, HC; Krishnan, A; Molina, A; Nademanee, A; Palmer, JM; Raubitschek, AA; Rodriguez, R; Spielberger, RT; Yamauchi, D | 1 |
| Bourhis, JH; Brice, P; Brousse, N; Decaudin, D; Gisselbrecht, C; Haioun, C; Morel, P; Quesnel, B; Souleau, B; Van Hoof, A | 1 |
| Diehl, V; Draube, A; Engert, A; Josting, A; Reiser, M; Rueffer, U; Söhngen, D; Tesch, H; Wickramanayake, PD; Wolf, J | 1 |
| Haas, R; Ho, AD; Hohaus, S; Martin, S; Moos, M; Pantel, G; Schmidt, P; Voso, MT; Weis, M | 1 |
| Carreras, E; Esteve, J; Fernández, F; Martínez, C; Montserrat, E; Perales, M; Rovira, M; Urbano-Ispizua, A | 1 |
| Alessandrino, EP; Arcaini, L; Astori, C; Bernasconi, P; Brusamolino, E; Cairoli, R; Calatroni, S; Colombo, AA; Gargantini, L; Iacona, I; Lazzarino, M; Morra, E; Orlandi, E; Pagnucco, G; Regazzi, MB | 1 |
| Ageli, S; Catovsky, D; Chau, I; Cunningham, D; Gill, K; Hill, M; Howard, A; Norman, A; Rao, S; Webb, A | 1 |
| Fox, RM; Grigg, AP; Seymour, JF; Szer, J | 1 |
| Dreger, P; Glass, B; Haas, R; Kneba, M; Kröger, N; Kuse, R; Martin, S; Parwaresch, R; Schmitz, N; Sonnen, R | 1 |
| Arnulf, B; Belanger, C; Bouabdallah, R; Brousse, N; Casasnovas, RO; Damaj, G; Delabesse, E; Delmer, A; Djabarri, M; Dreyfus, F; Hermine, O; Janvier, M; Lefrère, F; Levy, V; Maillard, N; McIntyre, E; Ribrag, V; Sebban, C; Suzan, F; Valensi, F; Varet, B; Verkarre, V | 1 |
19 review(s) available for cytarabine and Lymphoma, Mantle-Cell
| Article | Year |
|---|---|
Hematopoietic cell transplantation for mantle cell lymphoma.
Topics: Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Rituximab; Salvage Therapy; Transplantation, Autologous; Treatment Outcome | 2022 |
Initial and Consolidation Therapy for Younger Patients with Mantle Cell Lymphoma.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Autografts; Consolidation Chemotherapy; Cyclophosphamide; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lymphoma, Mantle-Cell; Quality of Life; Rituximab; Vincristine | 2020 |
Current Approaches to Mantle Cell Lymphoma: Diagnosis, Prognosis, and Therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclin D1; Cytarabine; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Prognosis; Rituximab | 2017 |
Optimizing therapy for mantle cell lymphoma.
Topics: Bendamustine Hydrochloride; Central Nervous System Neoplasms; Cytarabine; Humans; Lymphoma, Mantle-Cell; Rituximab | 2017 |
What is the optimal initial management of the younger mantle cell lymphoma patient?
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Risk Factors; Rituximab; Survival Rate; Transplantation, Autologous; Vincristine | 2018 |
Evolving treatment strategies in mantle cell lymphoma.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Autografts; Bendamustine Hydrochloride; Cytarabine; Humans; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Neoplasm, Residual; Rituximab; Stem Cell Transplantation | 2018 |
Mantle cell lymphoma: evolving management strategies.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cytarabine; Humans; Lymphoma, Mantle-Cell; Medical Oncology; Mutation; Positron-Emission Tomography; Prognosis; Pyrazines; Rituximab; Treatment Outcome | 2015 |
Mantle Cell Lymphoma.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Cytarabine; Drug Administration Schedule; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Molecular Targeted Therapy; Neoplasm Staging; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Risk Factors; Rituximab; Thalidomide; Transplantation, Autologous | 2016 |
High-dose cytarabine in mantle cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Autografts; Cyclophosphamide; Cytarabine; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Prednisone; Rituximab; Stem Cell Transplantation; Vincristine | 2015 |
Frontline therapy and role of high-dose consolidation in mantle cell lymphoma.
Topics: Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Algorithms; Allografts; Consolidation Chemotherapy; Cytarabine; Humans; Lymphoma, Mantle-Cell; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Stem Cell Transplantation | 2016 |
Dose-intense treatment of mantle cell lymphoma: can durable remission be achieved?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Prednisone; Remission Induction; Rituximab; Vincristine | 2008 |
Mantle cell lymphoma - does primary intensive immunochemotherapy improve overall survival for younger patients?
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocyte Subsets; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Genes, bcl-1; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Lymphoma, Mantle-Cell; Male; Middle Aged; Prednisone; Prognosis; Prospective Studies; Rituximab; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Vincristine | 2009 |
Autologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymphoma.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prednisone; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vincristine | 2009 |
Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Cell Proliferation; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Epidemiologic Methods; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Methotrexate; Middle Aged; Rituximab; Treatment Outcome; Vincristine | 2010 |
Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Asymptomatic Diseases; Biomarkers, Tumor; Bone Marrow Examination; Chemoradiotherapy; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 14; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Management; Doxorubicin; Female; Genes, bcl-1; Humans; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Risk Assessment; Rituximab; Salvage Therapy; Stem Cell Transplantation; Translocation, Genetic; Vincristine | 2012 |
Autologous transplantation and management of younger patients with mantle cell lymphoma.
Topics: Age Factors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Management; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Remission Induction; Rituximab; Survival Analysis; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2012 |
Emerging agents for the treatment of mantle cell lymphoma.
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drugs, Investigational; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Molecular Targeted Therapy; Prognosis; Pyrazines; Recurrence; Salvage Therapy; Sirolimus; Survival Analysis; TOR Serine-Threonine Kinases; Treatment Outcome; Watchful Waiting | 2012 |
Autologous stem cell transplantation in patients with mantle cell lymphoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Finland; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Life Tables; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prednisone; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2002 |
An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Prednisone; Radioimmunotherapy; Remission Induction; Rituximab; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Transplantation, Homologous; Vincristine | 2004 |
48 trial(s) available for cytarabine and Lymphoma, Mantle-Cell
| Article | Year |
|---|---|
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
Topics: Adenine; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Lymphopenia; Methotrexate; Middle Aged; Piperidines; Rituximab; Thrombocytopenia; Treatment Outcome; Vincristine | 2022 |
Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Ki-67 Antigen; Lactate Dehydrogenases; Lymphoma, Mantle-Cell; Middle Aged; Prednisone; Retrospective Studies; Rituximab; Transplantation, Autologous; Vincristine; Young Adult | 2022 |
Phase II study of bortezomib, cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cytarabine; Dexamethasone; Humans; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Treatment Outcome | 2023 |
Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Netherlands; Prednisone; Progression-Free Survival; Remission Induction; Rituximab; Transplantation, Autologous; Treatment Failure; Vincristine; Young Adult | 2020 |
Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Rituximab; Stem Cell Transplantation; Survival Rate; Vincristine | 2021 |
The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Cyclophosphamide; Cytarabine; Disease-Free Survival; DNA Mutational Analysis; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Mutation; Oxaliplatin; Prednisone; Primary Cell Culture; Rituximab; SAM Domain and HD Domain-Containing Protein 1; Tissue Array Analysis; Vidarabine; Vincristine | 2021 |
Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cytarabine; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Oxaliplatin; Prospective Studies; Rituximab; Transplantation, Autologous | 2021 |
R-MACLO-IVAM regimen followed by maintenance therapy induces durable remissions in untreated mantle cell lymphoma - Long term follow up results.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Male; Methotrexate; Middle Aged; Progression-Free Survival; Prospective Studies; Remission Induction; Rituximab; Thalidomide; Vincristine; Young Adult | 2021 |
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cytarabine; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Male; Middle Aged; Proportional Hazards Models; Rituximab; Survival Analysis; Transplantation, Autologous | 2017 |
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chemotherapy-Induced Febrile Neutropenia; Cyclophosphamide; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Incidence; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Rituximab; Survival Rate; Time Factors; Treatment Failure; Vincristine | 2018 |
R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Prednisone; Rituximab; Transplantation, Autologous; Vincristine; Young Adult | 2018 |
A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Rituximab; Survival Rate; Treatment Outcome; Vincristine | 2013 |
First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELT
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Pilot Projects; Prospective Studies; Rituximab; Treatment Outcome | 2013 |
Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Humans; Ki-67 Antigen; Lymphoma, Mantle-Cell; Male; Middle Aged; Remission Induction; Rituximab; SOXC Transcription Factors; Stem Cell Transplantation; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2013 |
Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC.
Topics: Adult; Age Factors; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Autografts; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning | 2014 |
Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Pyrazines; Recurrence; Remission Induction; Survival Analysis; Transplantation, Autologous | 2014 |
Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Multivariate Analysis; Neoplasm, Residual; Prognosis; Radioimmunotherapy; Stem Cell Transplantation; Time Factors; Transplantation, Autologous; Treatment Outcome | 2014 |
Zevalin and BEAM (Z-BEAM) versus rituximab and BEAM (R-BEAM) conditioning chemotherapy prior to autologous stem cell transplantation in patients with mantle cell lymphoma.
Topics: Adult; Aged; Algorithms; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cytarabine; Disease-Free Survival; Female; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Podophyllotoxin; Rituximab; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning | 2016 |
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Protocols; Autografts; Cytarabine; Female; Gene Deletion; Gene Dosage; Genes, p16; Genes, p53; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Lymphoma, Mantle-Cell; Male; Middle Aged; Prognosis | 2015 |
Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Rituximab; Vincristine | 2016 |
A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Disease-Free Survival; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Remission Induction; Rituximab; Survival Rate | 2016 |
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma N
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Immunotherapy; Lymphoma, Mantle-Cell; Male; Middle Aged; Prednisone; Transplantation Conditioning; Treatment Failure; Vincristine | 2016 |
RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Remission Induction; Rituximab; Transplantation, Autologous; Treatment Outcome; Vincristine; Young Adult | 2017 |
Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Female; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Rituximab; Salvage Therapy; Treatment Outcome | 2008 |
Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Recurrence; Rituximab; Salvage Therapy; Vincristine | 2008 |
High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Prednisone; Prognosis; Rituximab; Survival Analysis; Treatment Outcome; Vincristine | 2009 |
A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Pyrazines; Salvage Therapy; Survival Analysis | 2009 |
Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Immunotherapy; Lymphoma, Mantle-Cell; Male; Middle Aged; Prednisone; Recombinant Proteins; Rituximab; Survival Rate; Transplantation Conditioning; Vincristine | 2009 |
High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Remission Induction; Rituximab; Thalidomide; Treatment Outcome; Vincristine | 2010 |
[Clinical study of sequential high-dose chemotherapy with in vivo rituximab-purged stem cell autografting for mantle cell lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Female; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Mitoxantrone; Prednisolone; Pulse Therapy, Drug; Rituximab; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2010 |
Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Combined Modality Therapy; Cytarabine; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Ki-67 Antigen; Lymphoma, Mantle-Cell; Male; Middle Aged; Neutropenia; Prognosis; Prospective Studies; Rituximab; Stem Cell Transplantation; Thrombocytopenia; Transplantation, Autologous; Treatment Outcome; Vincristine; Young Adult | 2010 |
Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Female; Gene Frequency; Glutathione S-Transferase pi; Glutathione Transferase; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Peripheral Blood Stem Cell Transplantation; Polymorphism, Genetic; Survival Analysis; Time Factors; Treatment Outcome | 2010 |
Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Cell Proliferation; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Epidemiologic Methods; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Methotrexate; Middle Aged; Rituximab; Treatment Outcome; Vincristine | 2010 |
Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Pyrazines; Rituximab; Vincristine | 2010 |
Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Follow-Up Studies; Genetic Markers; Hematologic Diseases; Humans; Infections; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Methotrexate; Middle Aged; Prospective Studies; Rituximab; Treatment Outcome; Vincristine; Young Adult | 2012 |
Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective study
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Humans; Induction Chemotherapy; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Male; Prednisone; Rituximab; Treatment Outcome; Vidarabine; Vincristine | 2012 |
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Podophyllotoxin; Prognosis; Recurrence; Rituximab; Survival Rate; Transplantation, Autologous | 2012 |
CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Kidney Diseases; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Prednisone; Rituximab; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine; Whole-Body Irradiation | 2013 |
Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Drug Administration Schedule; Fatigue; Female; Humans; Kaplan-Meier Estimate; Leukopenia; Lymphoma, Mantle-Cell; Male; Middle Aged; Nausea; Neutropenia; Nitrogen Mustard Compounds; Positron-Emission Tomography; Remission Induction; Rituximab; Transplantation, Autologous; Treatment Outcome; Vomiting | 2013 |
A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bone Marrow Purging; Cytarabine; Female; Hematopoietic Stem Cell Mobilization; Humans; Immunophenotyping; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Rituximab; Salvage Therapy; Transplantation, Autologous | 2004 |
Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Disease-Free Survival; Doxorubicin; Etoposide; Follow-Up Studies; Humans; Life Tables; Lymphoma, Mantle-Cell; Peripheral Blood Stem Cell Transplantation; Prednisone; Prognosis; Prospective Studies; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Vincristine; Whole-Body Irradiation | 2004 |
Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chlorambucil; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Germany; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Prospective Studies; Survival Rate; Treatment Outcome; Vincristine | 2007 |
Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Radioimmunotherapy; Stem Cell Transplantation; Treatment Outcome; Yttrium Radioisotopes | 2008 |
Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Neoplasms, Second Primary; Recurrence; Survival Rate; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 2000 |
Dexa-BEAM: an effective regimen for cytoreduction prior to high-dose chemotherapy with autologous stem cell support for patients with relapsed/refractory mantle-cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Autologous | 2000 |
An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Transplantation, Autologous; Treatment Outcome | 2001 |
Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Prognosis; Recurrence; Salvage Therapy; Thrombocytopenia; Treatment Outcome; Vidarabine | 2002 |
The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Neoplasm Staging; Prednisolone; Prednisone; Prognosis; Survival Rate; Time Factors; Transplantation, Autologous; Treatment Outcome; Vincristine; Whole-Body Irradiation | 2000 |
81 other study(ies) available for cytarabine and Lymphoma, Mantle-Cell
| Article | Year |
|---|---|
Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Prednisone; Prospective Studies; Rituximab; Vincristine | 2022 |
Clinical and biological impact of SAMHD1 expression in mantle cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; SAM Domain and HD Domain-Containing Protein 1; Transplantation, Autologous | 2022 |
Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Melphalan; Retrospective Studies; Transplantation, Autologous | 2022 |
Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Retrospective Studies; Rituximab; Transplantation, Autologous; Treatment Outcome | 2023 |
Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective binational analysis between 2000 and 2020.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Retrospective Studies; Rituximab | 2023 |
Real-world treatment and outcome patterns of patients with mantle cell lymphoma in China: A large, multicenter retrospective analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Retrospective Studies; Treatment Outcome | 2023 |
Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL.
Topics: Adult; Aged; Bendamustine Hydrochloride; Cytarabine; Follow-Up Studies; Humans; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Prospective Studies; Rituximab | 2023 |
Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Pilot Projects; Rituximab | 2023 |
Rituximab/bendamustine/cytarabine for transplant-eligible patients with mantle cell lymphoma: A retrospective study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Cytarabine; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Prednisone; Retrospective Studies; Rituximab; Transplantation, Autologous; Vincristine | 2023 |
Treatment patterns and clinical outcomes of mantle cell lymphoma: A retrospective cohort study by CHOICE.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Hematopoietic Stem Cell Transplantation; Hepatitis B; Humans; Lymphoma, Mantle-Cell; Retrospective Studies; Rituximab | 2023 |
Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Drug Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Lymphoma, Mantle-Cell; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2019 |
Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Melphalan; Prospective Studies; Retrospective Studies; Transplantation, Autologous | 2020 |
Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Rituximab | 2020 |
Bilateral Infiltrative Optic Neuropathy of Systemic Mantle Cell Lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Central Nervous System Neoplasms; Cytarabine; Fundus Oculi; Humans; Lymphoma, Mantle-Cell; Male; Methotrexate; Optic Nerve; Optic Nerve Diseases; Rituximab | 2020 |
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lymphoma, Mantle-Cell; Retrospective Studies; Rituximab; Transplantation, Autologous | 2020 |
A case of "double hit" mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib.
Topics: Abnormal Karyotype; Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Bortezomib; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 8; Cyclin D1; Cytarabine; Drug Resistance, Neoplasm; Fatal Outcome; Gene Duplication; Genes, myc; Humans; Lymphoma, Mantle-Cell; Male; Oncogene Proteins, Fusion; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Rituximab; Translocation, Genetic | 2020 |
Cytarabine nanotherapeutics with increased stability and enhanced lymphoma uptake for tailored highly effective therapy of mantle cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Rituximab; Treatment Outcome | 2021 |
Extranodal blastoid/pleomorphic variant of mantle cell lymphoma involving the testis and skin.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Lymphoma, Mantle-Cell; Male; Oncogene Proteins, Fusion; Orchiectomy; Positron-Emission Tomography; Prednisone; Proto-Oncogene Proteins c-myc; Radiotherapy; Rituximab; Skin Neoplasms; Testicular Neoplasms; Vincristine | 2021 |
Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Disease Progression; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Outcome Assessment, Health Care; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Recurrence; Retrospective Studies; Rituximab; State Medicine; United Kingdom; Withholding Treatment | 2021 |
Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Proportional Hazards Models; Remission Induction; Retrospective Studies; Time-to-Treatment; Transplantation, Autologous; Vincristine | 2021 |
Progressive mantle cell lymphoma presenting with intractable pruritus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; Disease Progression; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Oxaliplatin; Pruritus; Rituximab | 2021 |
Treatment patterns and outcomes of older patients with mantle cell lymphoma in an Asian population.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Hypoalbuminemia; Induction Chemotherapy; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Male; Middle Aged; Progression-Free Survival; Retrospective Studies; Risk Factors; Rituximab; Singapore; Transplantation, Autologous | 2021 |
Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Proportional Hazards Models; Remission Induction; Retrospective Studies; Rituximab; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2017 |
Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 2018 |
Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Prednisone; Rituximab; Vincristine | 2018 |
R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Hospitalization; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Prednisone; Quality of Life; Remission Induction; Retrospective Studies; Rituximab; Survival Analysis; Transplantation, Autologous; Vincristine | 2018 |
Abdominal computed tomography angiography in post-transplantation sinusoidal obstruction syndrome associated with R-DHAOX/BEAM toxicity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Computed Tomography Angiography; Cytarabine; Dexamethasone; Etoposide; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Organoplatinum Compounds; Syndrome | 2018 |
Successful use of cytarabine and bendamustine in a patient with mantle cell lymphoma and acute renal failure using intermittent hemodialysis: A case report.
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Humans; Lymphoma, Mantle-Cell; Male; Renal Dialysis | 2019 |
Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity.
Topics: Antineoplastic Agents; Bortezomib; Cell Line, Tumor; Cytarabine; Deoxycytidine Kinase; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Lymphoma, Mantle-Cell; NF-kappa B; Signal Transduction; Transcription Factors; Transcription, Genetic | 2018 |
Kaposi's Sarcoma After Autologous Stem-Cell Transplantation and Rituximab Treatment.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphoma, Mantle-Cell; Male; Middle Aged; Oxaliplatin; Rituximab; Sarcoma, Kaposi; Transplantation, Autologous | 2018 |
[Analysis of Clinical Characteivstics and Therapeutic Efticacy of 54 Patients with Mantle Cell Lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis | 2018 |
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Cytarabine; Disease Progression; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Risk Factors; Survival Rate | 2019 |
Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Induction Chemotherapy; Lymphoma, Mantle-Cell; Male; Middle Aged; Rituximab | 2019 |
[Cytarabine and hematopoietic cell transplantation for mantle cell lymphoma. Analysis of 20 patients].
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Combined Modality Therapy; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Retrospective Studies; Risk Factors; Rituximab; Sex Distribution; Statistics, Nonparametric; Time Factors; Treatment Outcome | 2019 |
The effect of high-dose cytarabine followed by autologous hematopoietic stem cell transplantation on the outcome of patients with mantle cell lymphoma.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Retrospective Studies; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2020 |
A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease Progression; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Induction Chemotherapy; International Cooperation; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies; Transplantation Conditioning; Treatment Outcome | 2019 |
Prognostic impact of monocyte count at presentation in mantle cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Italy; Kaplan-Meier Estimate; Leukocyte Count; Leukocytes; Lymphatic Irradiation; Lymphocytes; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Monocytes; Prednisolone; Prednisone; Prognosis; Proportional Hazards Models; Risk; Splenectomy; Stem Cell Transplantation; Switzerland; Transplantation, Autologous; Treatment Outcome; Vincristine | 2013 |
Rituximab, Ara-C, dexamethasone and oxaliplatin (R-ADOx) is effective for treatment of elderly patients with relapsed mantle cell lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Rituximab; Treatment Outcome | 2013 |
High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Lymphoma, Mantle-Cell; Rituximab; Treatment Failure; Treatment Outcome | 2014 |
Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC.
Topics: Adult; Age Factors; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Autografts; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning | 2014 |
Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclophosphamide; Cytarabine; DNA Damage; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Inhibitory Concentration 50; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Multiple Myeloma; Pyrimidines; Rituximab | 2014 |
Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Cohort Studies; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Staging; Peripheral Blood Stem Cell Transplantation; Prednisone; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Rituximab; Vincristine | 2014 |
[Current treatment strategy in mantle cell lymphoma].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Humans; Lymphoma, Mantle-Cell; Rituximab; Stem Cell Transplantation | 2014 |
How to manage mantle cell lymphoma.
Topics: Aged; Algorithms; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents; Combined Modality Therapy; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Middle Aged; Neoplasm Staging; Prognosis; Rituximab; Watchful Waiting | 2014 |
Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cladribine; Clone Cells; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Down-Regulation; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Mass Spectrometry; Mice; Proteomics; Rituximab; Vidarabine; Xenograft Model Antitumor Assays | 2014 |
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melphalan; Nitriles; Nitrogen Mustard Compounds; Prednisone; Primary Myelofibrosis; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Rituximab; Vincristine | 2014 |
The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Consensus Development Conferences as Topic; Cytarabine; Europe; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Lymphoma, Mantle-Cell; Neoplasm, Residual; Positron-Emission Tomography; Recurrence; Remission Induction; Rituximab; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2015 |
Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cytarabine; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Risk; Rituximab; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2015 |
Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Cytarabine; Dose-Response Relationship, Drug; Humans; Lymphoma, Mantle-Cell; Middle Aged; Stem Cell Transplantation; Whole-Body Irradiation | 2016 |
Long-term follow-up of (90)Y-ibritumomab-tiuxetan ((90)YIT) in the conditioning of autologous hematopoietic transplantation for indolent and mantle cell lymphomas in a single French center.
Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Follow-Up Studies; France; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Radioimmunotherapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Yttrium Radioisotopes | 2016 |
Late-onset meningeal lymphomatosis in mantle cell lymphoma controlled with chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Injections, Spinal; Lymphoma, Mantle-Cell; Meningeal Neoplasms; Middle Aged; Prednisone; Rituximab; Vincristine | 2018 |
[Mantle cell lymphoma, response to treatment and prognosis in 45 patients].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2016 |
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; Cytarabine; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Thalidomide; Tumor Suppressor Protein p53; Vidarabine | 2016 |
Haematological cancer: Cytarabine - new standard of care for MCL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Hematologic Neoplasms; Humans; Lymphoma, Mantle-Cell; Rituximab; Standard of Care | 2016 |
Single-agent cytarabine is insufficient for the treatment of human mantle cell lymphoma in mouse xenograft model.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Models, Animal; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Mice; Mice, Inbred NOD; Mice, SCID; Prednisone; Treatment Outcome; Vincristine; Xenograft Model Antitumor Assays | 2016 |
Bendamustine-rituximab in mantle cell lymphoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Humans; Lymphoma, Mantle-Cell; Rituximab | 2017 |
Results from the Belgian mantle cell lymphoma registry.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Belgium; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Hepatomegaly; Humans; Lymphadenopathy; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Registries; Retrospective Studies; Rituximab; Splenomegaly; Transplantation, Autologous; Young Adult | 2017 |
Rituximab-induced acute thrombocytopenia: a case report and review of the literature.
Topics: Acute Disease; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Humans; Immunophenotyping; Infusions, Parenteral; L-Lactate Dehydrogenase; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Platelet Count; Rituximab; Splenomegaly; Thrombocytopenia; Vincristine | 2009 |
Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Ki-67 Antigen; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Prognosis; Rituximab; Survival Analysis; Vincristine | 2009 |
Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Administration Schedule; Eukaryotic Initiation Factor-4E; Female; Humans; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Prognosis; Rituximab; Survival Analysis; Treatment Outcome; Vincristine | 2009 |
Effective clearance of Ara-U the major metabolite of cytosine arabinoside (Ara-C) by hemodialysis in a patient with lymphoma and end-stage renal failure.
Topics: Antimetabolites, Antineoplastic; Arabinofuranosyluracil; Chromatography, High Pressure Liquid; Cytarabine; Female; Humans; Kidney Failure, Chronic; Lymphoma, Mantle-Cell; Middle Aged; Neurotoxicity Syndromes; Renal Dialysis | 2011 |
Simultaneous bilateral spontaneous pneumothorax following high-dose chemotherapy and bone marrow transplantation for mantle cell lymphoma without evidence of pulmonary disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Humans; Lung Diseases; Lymphoma, Mantle-Cell; Melphalan; Middle Aged; Pneumothorax; Prognosis | 2010 |
Front-line treatment of mantle cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Combined Modality Therapy; Cytarabine; Dexamethasone; Disease-Free Survival; Humans; Ki-67 Antigen; Lymphoma, Mantle-Cell; Neutropenia; Prognosis; Stem Cell Transplantation; Thrombocytopenia; Transplantation, Autologous; Treatment Outcome; Vincristine | 2010 |
Inhibition of GST-pi nuclear transfer increases mantle cell lymphoma sensitivity to cisplatin, cytarabine, gemcitabine, bortezomib and doxorubicin.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Cytarabine; Deoxycytidine; Doxorubicin; Drug Screening Assays, Antitumor; Gemcitabine; Glutathione S-Transferase pi; Humans; Lectins; Lymphoma, Mantle-Cell; Pyrazines | 2010 |
Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Leukapheresis; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Time Factors; Transplantation, Autologous; Treatment Outcome; Vincristine | 2011 |
Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Patient Selection; Predictive Value of Tests; Remission Induction; Risk Assessment; Risk Factors; Transplantation, Autologous; Treatment Outcome | 2011 |
The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bendamustine Hydrochloride; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytarabine; Drug Synergism; Flow Cytometry; Humans; Lymphoma, Mantle-Cell; Mitochondria; Nitrogen Mustard Compounds | 2012 |
High dose cytarabine with rituximab is an effective first-line therapy for mantle cell lymphoma and produces ample stem cell harvest yields after multiple chemotherapy cycles.
Topics: Antimetabolites, Antineoplastic; Cytarabine; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Transplantation, Homologous; Treatment Outcome | 2013 |
[A patient with mantle cell lymphoma who successfully underwent auto-PBSCT in combination with in vivo purging of tumor cells using rituximab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Purging; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Lymphoma, Mantle-Cell; Methotrexate; Middle Aged; Prednisone; Remission Induction; Rituximab; Transplantation, Autologous; Vincristine | 2002 |
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Purging; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Humans; Leukapheresis; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Mitoxantrone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Polymerase Chain Reaction; Remission Induction; Retrospective Studies; Rituximab; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2003 |
[Anti-CD20 antibody and combination chemotherapy followed by autologous peripheral blood stem cell transplantation after high-dose chemotherapy induced complete remission in a case of multiple lymphomatous polyposis of the gastrointestinal tract].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Drug Administration Schedule; Etoposide; Humans; Intestinal Neoplasms; Intestinal Polyposis; Lymphoma, Mantle-Cell; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Remission Induction; Rituximab | 2003 |
Suboccipital lateral injection of intrathecal chemotherapy in a patient with mantle cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cerebrospinal Fluid; Chemotherapy, Adjuvant; Cytarabine; Dexamethasone; Humans; Injections, Spinal; Lymphoma, Mantle-Cell; Male; Meningeal Neoplasms; Palliative Care; Spinal Cord Neoplasms | 2004 |
[Mantle cell lymphoma markedly infiltrated into adrenal glands with adrenal insufficiency].
Topics: Adrenal Gland Neoplasms; Adrenal Insufficiency; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Humans; Hydrocortisone; Lymphoma, Mantle-Cell; Male; Methylprednisolone Hemisuccinate; Neoplasm Invasiveness; Prednisolone; Treatment Outcome; Vincristine | 2004 |
[Two cases of malignant lymphoma with high fever and C-reactive protein (CRP) elevation after treatment with granulocyte colony-stimulating factor (G-CSF)].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma; Lymphoma, Mantle-Cell; Male; Middle Aged; Prednisone; Recombinant Proteins; Rituximab; Vincristine | 2006 |
Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Rituximab; Survival Rate; Transplantation, Autologous | 2006 |
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 14; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Evaluation; Follow-Up Studies; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Genes, Immunoglobulin; Humans; Immunoglobulin Heavy Chains; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Mitoxantrone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Polymerase Chain Reaction; Prednisone; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Salvage Therapy; Translocation, Genetic; Transplantation, Autologous; Vincristine | 2006 |
Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prednisone; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Radioimmunotherapy; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Vidarabine; Vincristine; Yttrium Radioisotopes | 2007 |
In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Immunosuppressive Agents; Leukapheresis; Lymphocyte Depletion; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Pilot Projects; Polymerase Chain Reaction; Prednisone; Rituximab; Transplantation, Autologous; Vincristine; Whole-Body Irradiation | 2000 |
Patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 2000 |
A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Purging; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Gene Rearrangement; Genes, bcl-2; Half-Life; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Metabolic Clearance Rate; Middle Aged; Polymerase Chain Reaction; Prednisone; Recurrence; Rituximab; Transplantation, Autologous; Vincristine | 2002 |
Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Prospective Studies; Survival Rate; Treatment Outcome; Vincristine | 2002 |